

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: ${ t V}$	Norld J	Iournal of	f Gastroenterol	ogy
---------------------------	---------	------------	-----------------	-----

Manuscript NO: 75502

Title: Evaluating the best treatment for multifocal hepatocellular carcinoma: a

propensity score-matched analysis

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03912378 Position: Peer Reviewer Academic degree: BSc, PhD

Professional title: Professor

Reviewer's Country/Territory: Australia

Author's Country/Territory: Italy

Manuscript submission date: 2022-02-01

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-02-02 02:49

Reviewer performed review: 2022-02-05 12:22

Review time: 3 Days and 9 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish	
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection	
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection	
Re-review	[Y]Yes []No	



Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

Peer-reviewer

Peer-Review: [] Anonymous [Y] Onymous

statements Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

There were few patients included in this paper, which means that the statistics are more likely to show no difference between groups. Therefore, the title, abstract, Core tips and Conclusions should be modified to include wording that conveys the small study size. Teh introduction states that organ shortage for transplant 'cannot be overcome'. This wording is too strong; nothing is impossible and so it is possible that the organ shortfall issue can be alleviated.



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: ${ t V}$	Norld J	Iournal of	f Gastroenterol	ogy
---------------------------	---------	------------	-----------------	-----

Manuscript NO: 75502

Title: Evaluating the best treatment for multifocal hepatocellular carcinoma: a

propensity score-matched analysis

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02579144 Position: Editorial Board Academic degree: MD, PhD

Professional title: Assistant Professor, Doctor

Reviewer's Country/Territory: Japan

Author's Country/Territory: Italy

Manuscript submission date: 2022-02-01

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-02-03 04:22

Reviewer performed review: 2022-02-06 00:17

Review time: 2 Days and 19 Hours

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [] Minor revision [Y] Major revision [] Rejection
Re-review	[Y]Yes []No



Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

Peer-reviewer statements

Peer-Review: [Y] Anonymous [] Onymous

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

To the authors: "Evaluating the best treatment for multifocal hepatocellular carcinoma: a propensity score-matched analysis" My comments are as follows. 1. Please show the rationale for setting the cut-off value of AFP to 400 ng/mL. 2. Please evaluate the HCC stage also with the Up-to-7 criteria. 3. Please show the detailed breakdown of Child-Pugh score in Tables. 4. How did you judge whether liver cirrhosis be present or not? 5. You mentioned "In patients with multifocal HCC, considering similar post-procedural morbidity, LR confers longer DFS compared with TACE, but without differences in OS.". As you know, drug therapy, including immunotherapy, is also the treatment option for multifocal HCC. How do you think about the proper use of drug therapy, LR or TACE for multifocal HCC? Please explain your opinion. I hope that my comments will be useful in improving the article.